Does neuroinflammation sustain neurodegeneration in ALS?

Amyotrophic lateral sclerosis (ALS), the most prevalent type of motor neuron disease in adults, affecting 4–6 per 100,000, is a fatal neurodegenerative disease. ALS is characterized by the degeneration of both upper motor neurons comprising the corticospinal tract and lower motor neurons arising from the brainstem nuclei and ventral roots of the spinal cord. The only drug approved for ALS—riluzole—provides a modest survival benefit. An improved understanding of the pathophysiology of ALS has potential for the development of more effective therapeutic interventions.

The death of neurons in ALS is accompanied by a neuroinflammatory response that is characterized by microglial activation and T-cell infiltration in affected regions. However, an understanding of inflammation in ALS, as harmful, protective, or both, is elusive. Microglia represent the first line of defense in the CNS, and is the first cell type to be activated in case of injury. Microglial activation may be cytotoxic in ALS, particularly late in the disease process. Further, activated microglia might have a protective role in CNS injury, including motor neuron death, through the release of anti-inflammatory cytokines and growth factors. Understanding the relationships between neurodegeneration and neuroinflammation in ALS is thus critical if they are to be harnessed for therapeutic purposes.

Over the last 2 decades, structural, functional, and molecular neuroimaging findings have changed our understanding of the pathophysiology of ALS by providing the means to visualize in vivo the propagation of pathology. Activated microglia are characterized by high expression of the 18 kDa translocator protein (TSPO), formerly known as the peripheral benzodiazepine receptor (PBR), on mitochondria, and PET radiotracers binding to TSPO allow an in vivo assessment of microglia activation in the brain. The first application of TSPO PET in patients with ALS showed increased binding in the motor cortex, pons, dorsolateral prefrontal cortex, and thalamus, where the extent of microgliosis was positively correlated with the severity of ALS. Increased TSPO expression was subsequently reported in the primary motor cortex, supplementary motor area, as well as temporal cortex of patients with ALS, giving support to a role for inflammatory processes in ALS. This piece of evidence is strengthened by the findings that myo-inositol, a spectroscopic marker of glial activity, is increased in the primary motor cortex of patients with ALS.

In this issue of Neurology®, Alshikho et al. elegantly use a combination of MRI and PET techniques to help advance our understanding of the role of glial cells in ALS pathogenesis. In 10 patients with ALS, the authors interrogated the relationship between glial activation, measured by $[^{11}C]$-PBR28 PET, and the location of structural brain abnormalities, measured by diffusion tensor MRI and cortical thickness. Increased expression of the glial marker $[^{11}C]$-PBR28 colocalized with reduced fractional anisotropy (FA) in the upper part of the corticospinal tract and with cortical thinning of the precentral gyrus. Moreover, increased $[^{11}C]$-PBR28 in the left motor cortex correlated with FA reduction and cortical thinning. All 3 measures ($[^{11}C]$-PBR28, FA, and cortical thickness) were strongly associated with clinical upper motor neuron impairment.

Although limited by the small number of patients and by the relatively advanced disease in some of them, this study provides in vivo a link between disease mechanisms (gliosis and inflammation) and structural alterations (cortical thinning and white matter changes). The main unanswered question, however, is whether the structural brain abnormalities are the consequence or the cause of the neuroinflammation. Longitudinal studies are warranted to address the temporal sequences of events and to explore whether the assessment of microglial activation can help to predict the pattern of pathologic spreading in ALS. Longitudinal, multimodal neuroimaging studies of presymptomatic individuals carrying ALS-related mutations would offer an unprecedented opportunity to determine the order and rate of brain changes in the presymptomatic stage of the disease. Together with the findings by Alshikho et al., these future studies would clarify whether therapeutic modulation of the inflammatory response could provide an opportunity to alter disease progression in ALS.
Another important but still unexplored issue hinders translation into clinical application, i.e., whether $[^{11}\text{C}]-\text{PBR28}$ PET is sufficiently sensitive to detect change over time. Future studies will need to determine its potential as a robust pharmacodynamic marker to monitor in vivo the efficacy of treatments targeting neuroinflammation in ALS, not only at the group level but more critically in individual patients.

STUDY FUNDING
No targeted funding reported.

DISCLOSURE
M. Filippi is Editor-in-Chief of Journal of Neurology; serves on scientific advisory board for Teva Pharmaceutical Industries; has received compensation for consulting services and/or speaking activities from Bayer Schein Pharma, Biogen Idec, EXCEMED, Merck Serono, and Teva Pharmaceuticals Industries; and receives research support from Bayer Schein Pharma, Biogen Idec, Merck Serono, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, Cure PSP, Alzheimer’s and Drug Discovery Foundation, and the Jacques and Gloria Gossweiler Foundation (Switzerland). F. Agosta serves on the editorial board of the Journal of Neurology and has received research support from the Italian Ministry of Health, AriSLA–Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica and the European Research Council and speaker honoraria from EXCEMED–Excellence in Medical Education. Go to Neurology.org for full disclosures.

REFERENCES